Table 3.
Odds of progression of radiographic damage ranked by effect size: therapy plus methotrexate versus methotrexate
| Agent | Trial | Treatment* | Placebo* | OR (95% CI) |
|---|---|---|---|---|
| Infliximab | Breedveld et al14 | 24% | 83% | 0.07 (0.02, 0.29) |
| Lipsky et al13 | 11% | 31% | 0.26 (0.14, 0.50) | |
| Pooled | 0.19 (0.09, 0.41) | |||
| Etanercept | Klareskog et al6 | 20% | 43% | 0.34 (0.21, 0.54) |
| Emery et al7 | 20% | 41% | 0.36 (0.23, 0.56) | |
| Pooled | 0.35 (0.26, 0.47) | |||
| Tocilizumab | Kremer et al19 | 16% | 33% | 0.39 (0.25, 0.62) |
| Adalimumab | Breedveld et al12 | 36% | 63% | 0.33 (0.22, 0.51) |
| Keystone et al11 | 38% | 54% | 0.52 (0.33, 0.83) | |
| Pooled | 0.41 (0.27, 0.64) | |||
| Certolizumab pegol | Keystone et al8 | 31% | 48% | 0.48 (0.34, 0.69) |
| Keystone et al9 | 26% | 41% | 0.51 (0.35, 0.75) | |
| Pooled | 0.50 (0.38, 0.64) | |||
| Rituximab | Cohen et al16 | 43% | 61% | 0.48 (0.33, 0.71) |
| Tak et al17 | 36% | 47% | 0.64(0.44, 0.93) | |
| Pooled | 0.57 (0.43, 0.76) | |||
| Golimumab | Emery et al15 | 31% | 40% | 0.64 (0.44, 0.94) |
| Abatacept | Westhovens et al21 | 39% | 47% | 0.71 0.49, 1.03) |
Note:
*
Treatment refers to biologic DMARD plus methotrexate while placebo refers to the methotrexate plus placebo group. Bold text indicates pooled results for each agent.
Abbreviations: CI, confidence interval; DMARD, disease-modifying anti-rheumatic drug; OR, odds ratio.